What is the future of immunotherapy in multiple myeloma? | Zendy

Leo Rasche | Zendy; Michael Hudecek | Zendy; Hermann Einsele | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

What is the future of immunotherapy in multiple myeloma?

Author(s) -

Leo Rasche,

Michael Hudecek,

Hermann Einsele

Publication year - 2020

Publication title -

blood

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.515

H-Index - 465

eISSN - 1528-0020

pISSN - 0006-4971

DOI - 10.1182/blood.2019004176

Subject(s) - multiple myeloma , immunotherapy , medicine , immunology , transplantation , monoclonal antibody , autologous stem cell transplantation , immune system , antibody , oncology

The treatment of multiple myeloma (MM) is currently being redefined by humoral and cellular immunotherapies. For decades, there was limited belief in immune-based anti-MM therapy as a result of the moderate graft-versus-myeloma effect of allogeneic stem cell transplantation. Today, monoclonal antibodies comprise the new backbone of anti-MM therapy, and T-cell therapies targeting BCMA are emerging as the most potent single agents for MM treatment. Herein, we present our assessment of and vision for MM immunotherapy in the short and midterm.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research